CD274 and non-small cell lung carcinoma: In particular, in the CheckMate 227 trial, NSCLC patients with high TMB (> 10 mutations per Mb, measured by FoundationOne) presented increased progression-free survival after combined anti-CTLA-4 plus anti-PD-1/PD-L1 therapy [45].